A Form 4 filed on September 16, 2026 with the U.S. Securities and Exchange Commission discloses that Ugur Sahin, Chief Executive Officer of BioNTech SE (NASDAQ:BNTX), sold a combined 49,000 ordinary shares on September 15 and September 16, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Two-day sale: Sahin disposed of 34,000 ordinary shares on September 15, 2026 at $96.4893 per share, and 15,000 ordinary shares on September 16, 2026 at $96.0893 per share.
  • Direct holdings after transactions: Following the sales, Sahin directly holds 553,209 ordinary shares.
  • Indirect holdings: An additional 39,218,111 ordinary shares are held indirectly through Medine GmbH, of which Sahin is the sole shareholder.
  • Trust arrangement: Of the indirectly held shares, 106,721 are held for the benefit of an individual under a trust arrangement, over which Medine GmbH exercises voting power but not dispositive power.
  • Trading plan: The filing states the sales were made pursuant to a Rule 10b5-1 trading plan established by Sahin on June 3, 2026.
  • Transaction codes: Both transactions are coded "S" (sale) in the filing.

Details of Ugur Sahin's Share Dispositions and Beneficial Ownership at BioNTech

According to the filing, Ugur Sahin, who serves as Chief Executive Officer and is also identified as a 10% owner of BioNTech SE, directly sold 34,000 ordinary shares on September 15, 2026 at a price of $96.4893 per share. The following day, September 16, 2026, he disposed of an additional 15,000 ordinary shares at $96.0893 per share. After these transactions, the filing reports his direct beneficial ownership at 553,209 ordinary shares.

The filing also discloses that Sahin indirectly holds 39,218,111 ordinary shares through Medine GmbH, an entity for which he is the sole shareholder. The filing notes that 106,721 of those indirectly held shares are subject to a trust arrangement under which Medine GmbH "exercises voting power, but not dispositive power" over those shares for as long as they remain in trust. The filing states that "the reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH."

The filing indicates that both sales were "effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026." The form was signed by Humza Bokhari as Attorney-in-Fact on September 16, 2026, and the box confirming a Rule 10b5-1(c) transaction was checked on the filing.

What Was Disclosed

BioNTech SE's CEO Ugur Sahin sold 49,000 ordinary shares across two dates in September 2026 under a pre-established Rule 10b5-1 plan, with direct ownership falling to 553,209 shares and indirect ownership of 39,218,111 shares remaining through Medine GmbH.